Immunotherapeutic strategy | Adjuvant/interventions | Indications | Phase | Trial ID |
---|---|---|---|---|
Anti-NY-ESO-1 TCR | Cyclophosphamide | Synovial sarcoma, melanoma, esophageal cancer, ovarian cancer, lung cancer, bladder cancer, liver cancer | 1 | NCT02869217 |
Cyclophosphamide + transforming growth factor-beta receptor II (TGFbDNRII)-transduced autologous tumor infiltrating lymphocytes | Adult solid neoplasm | 1 and 2 | NCT02650986 | |
Cyclophosphamide | Bone Sarcoma, soft tissue sarcoma, melanoma, liver cancer, esophageal cancer, breast cancer, thyroid cancer, ovarian cancer | 1 | NCT03159585 | |
None | Advanced malignant solid tumors | 1 | NCT03047811 | |
Cyclophosphamide, fludarabine | Bladder carcinoma, breast cancer, esophagus carcinoma, lung cancer, melanoma, multiple myeloma, neuroblastoma, ovarian cancer, synovial sarcoma, other metastatic solid cancers | 1 | NCT02457650 | |
Aldesleukin, cyclophosphamide, decitabine | Recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma | 1 | NCT03017131 | |
Cyclophosphamide | Lung cancer, non-small cell lung cancer | Â | NCT03029273 | |
Pembrolizumab | Multiple myeloma | 1 | NCT03168438 | |
NY-ESO-1 TCR + NY-ESO-1 peptide Vaccine | Aldesleukin, cyclophosphamide, fludarabine phosphate, nivolumab | Neoplasms | 1 | NCT02775292 |
NY-ESO-1 TCR+ NY-ESO-1 protein vaccine | Cyclophosphamide, fludarabine phosphate, aldesleukin, radiation | Solid tumors | 1 | NCT02366546 |
NY-ESO-1 protein vaccine | Atezolizumab, guadecitabine, carboxymethylcellulose, polyinosinic-polycytidylic acid, and poly-l-lysine (Poly ICLC) | Recurrent fallopian tube carcinoma Recurrent ovarian carcinoma Recurrent primary peritoneal carcinoma | 1 and 2 | NCT03206047 |
NY-ESO-1 peptide vaccine | Montanide ISA-51, polyinosinic-polycytidylic acid, and poly-l-lysine (Poly ICLC), Cyclophosphamide, Fludarabine, Interleukin-2 | Melanoma | 2 | NCT02334735 |